Stenoparib wins FDA fast track status for advanced ovarian cancer
The U.S. Food and Drug Administration (FDA) has given fast track status to stenoparib, an experimental treatment Allarity Therapeutics has been testing for advanced…
Gynecological cancer
Gynecological cancer overview
Gynecological cancer encompasses a group of cancers affecting the female reproductive system. Approximately 100,000 people are diagnosed with gynecological cancer in the U.S. every year. Although each type of gynecological cancer is unique, with its own symptoms, risk factors, and treatment options, reaching an early diagnosis is critical for ensuring the best possible outcomes in any of them.
Read moreGynecological cancer treatment
There are several treatment approaches for gynecological cancer, which encompasses all cancers that originate in the female reproductive system. The choice of treatment will depend on the cancer type, how far it has spread, a patient’s general health status, and other factors, such as whether the patient wishes for their fertility to be preserved.
Read moreNews
Ovarian cancer patients wanted for Phase 3 trial of virus therapy
A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
2 of 3 ovarian cancer patients in study respond to SON-1010 combo
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more patients — and soon, at…
Intervenn’s noninvasive ovarian cancer test to hit market this fall
A noninvasive diagnostic test to help distinguish ovarian cancer from benign pelvic masses will be available this fall. GlycoKnow Ovarian received a proprietary laboratory…
Projections show uterine cancer cases, mortality rate, on rise in US
The number of uterine cancer cases and related deaths — the disease’s incidence and mortality rates — in the U.S. are expected to substantially rise…
Approval sought of relacorilant for platinum-resistant ovarian cancer
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…
